Subclinical depressive symptoms and continued cannabis use: Predictors of negative outcomes in first episode psychosis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  González Ortega, Itxaso ^a   Alberich, Susana ^a   Echeburúa, Enrique ^a   Aizpuru, Felipe ^b   Millán, Eduardo ^c   Vieta, Eduard ^d   Matute, Carlos ^a   González Pinto, Ana ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Araba Primary Care Unit   (Spain)

^c Subdirección de Asistencia Sanitaria   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SOCIAL STATUS; ANALYSIS OF VARIANCE; COMPLICATION; MIDDLE AGED; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIOECONOMICS; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

CANNABIS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SOCIOECONOMIC FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84929469827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123707     Document Type: Article

References (52)

1. Wu LT, Gersing K, Burchett B, Woody GE, Blazer DG (2011) Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res 45:1453-1462. doi: 10.1016/j.jpsychires.2011.06.012 PMID: 21742345
2. Wu LT, Blazer DG, Gersing KR, Burchett B, Swartz MS, Mannelli P, et al. (2013) Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race people. J Psychiatr Res 47:1940-1948. doi: 10.1016/j.jpsychires.2013.08.022 PMID: 24060266
3. Chen R, Zhang J, Fan N, Teng Z, Wu Y, Yang H, et al. (2013) Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 155:1154-1165. doi: 10.1016/j.cell.2013.10.042 PMID: 24267894
4. Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383-1391. doi: 10.1016/S0140-6736(09)61037-0 PMID: 19837255
5. Van Gastel W.A, Tempelaar W, Bun C, Schubart CD, Kahn RS, Plevier C, et al. (2013) Cannabis use as an indicator of risk for mental health problems in adolescents: a population-based study at secondary schools. Psychol Med 43:1849-1856. doi: 10.1017/S0033291712002723 PMID: 23200103
6. Barrigón ML, Gurpegui M, Ruiz-Veguilla M, Diaz FJ, Anguita M, Sarramea F,et al. (2010) Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res 44:413-420. doi: 10.1016/j.jpsychires.2009.10.004 PMID: 19900684
7. Ruiz-Veguilla M, Barrigón ML, Hernández L. Rubio JL, Gurpegui M, Sarramea F, et al. (2013) Dose-response effect between cannabis use and psychosis liability in a non-clinical population: evidence from a snowball sample. J Psychiatr Res 47:1036-1043. doi: 10.1016/j.jpsychires.2013.03.003 PMID: 23684550
8. Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JMA, et al. (2013) Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: 18F-Fallypride Positron Emission Tomography Study. Plos One 8(7): e70378. doi: 10.1371/journal.pone.0070378 PMID: 23936196
9. González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutiérrez M, et al. (2008) Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 69:1210-1216. PMID: 18681755
10. Moore TH, Zammit S, Lingford-Hughes A (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319-328. PMID: 17662880
11. Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al. (2014) Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 44:499-506. doi: 10.1017/S0033291713000883 PMID: 23701858
12. Barrowclough C, Emsley R, Eisner E, Beardmore R, Wykes T (2013). Does change in cannabis use in established psychosis affect clinical outcome? Schizophr Bull 39:339-348. doi: 10.1093/schbul/sbr152 PMID: 22037770
13. Clausen L, Hjorthøj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, et al. (2014) Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 44:117-126. doi: 10.1017/S0033291713000433 PMID: 23590927
14. González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, et al. (2011) Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 37: 631-639. doi: 10.1093/schbul/sbp126 PMID: 19915168
15. Hjorthøj CR, Orlovska S, Fohlmann A, Nordentoft M (2013) Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis. Schizophr Res 151:191-196. doi: 10.1016/j.schres.2013.10.014 PMID: 24189290
16. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al. (2013) A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res 143:138-142. doi: 10.1016/j.schres.2012.10.018 PMID: 23187069
17. Degenhardt L, Hall W, Lynskey M (2003). Exploring the association between cannabis use and depression. Addiction 98:1493-1504. PMID: 14616175
18. Gregg L, Haddock G, Emsley R, Barrowclough C (2014) Reasons for substance use and their relationship to subclinical psychotic and affective symptoms, coping, and substance use in a nonclinical sample. Psychol Addict Behav 28:247-256. doi: 10.1037/a0034761 PMID: 24274439
19. Hartley S, Barrowclough C, Haddock G (2013) Anxiety and depression in psychosis: a systematic review of associations with positive psychotic symptoms. Acta Psychiatr Scand 128:327-346. doi: 10.1111/acps.12080 PMID: 23379898
20. Cotton SM, Lambert M, Schimmelmann BG, Mackinnon A, Gleeson JF, Berk M, et al. (2012) Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophr Res 134:20-26. doi: 10.1016/j.schres.2011.08.018 PMID: 21937197
21. Riedel M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, et al. (2012) Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J Biol Psychiatry 13:30-38. doi: 10.3109/15622975.2011.552633 PMID: 21568628
22. Romm KL, Rossberg JI, Berg AO, Barrett EA, Faerden A, Agartz I, et al. (2010) Depression and depressive symptoms in first episode psychosis. J Nerv Ment Dis 198:67-71. doi: 10.1097/NMD.0b013e3181c81fc0 PMID: 20061872
23. Sönmez N, Romm KL, Andreasssen OA, Melle I, Røssberg JI (2013) Depressive symptoms in first episode psychosis: a one-year follow-up study. BMC Psychiatry 13:106. doi: 10.1186/1471-244X-13-106 PMID: 23560591
24. Upthegrove R, Birchwood M, Ross K, Brunett K, McCollum R, Jones L (2010). The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand 122:211-218. doi: 10.1111/j.1600-0447.2009.01506.x PMID: 19922525
25. Schofield D, Tennant C, Nash L, Degenhardt L, Cornish A, Hobbs C, et al. (2006) Reasons for cannabis use in psychosis. Aust NZJ Psychiatry 40:570-574. PMID: 16756582
26. Denson TF, Earleywine M (2006). Decreased depression in marijuana users. Addict Behav 31:738-742. PMID: 15964704
27. Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, et al. (2013) The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res 47:438-444. doi: 10.1016/j.jpsychires.2012.11.009 PMID: 23290558
28. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594-608. PMID: 15780846
29. Lev-Ran S, Roerecke M, Le Foll B, George TP, Mckenzie K, Rehm J (2014) The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44:797-810. doi: 10.1017/S0033291713001438 PMID: 23795762
30. Otten R, Engels RC (2013) Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene. Addict Biol 18:826-835. doi: 10.1111/j.1369-1600.2011.00380.x PMID: 21967091
31. Allsop DJ, Copeland L, Norberg MM, Fu S, Molnar A, Lewis J, Budney AJ (2012) Quantifying the Clinical Significance of Cannabis Withdrawal. PLoS One: 7(9):e44864. doi: 10.1371/journal.pone.0044864 PMID: 23049760
32. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington: DC.
33. Kokkevi A, Hartgers C (1995) EUROP-ASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1:208-210.
34. First MB, Spitzer R, Gibbon M (1997) Structured Clinical Interview for DSM-IV Axis I Disorders. Washington DC: American Psychiatric Press Inc.
35. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. PMID: 3616518
36. Peralta MV, Cuesta ZMJ (1994) Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 22:171-177. PMID: 7810373
37. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296. PMID: 6080235
38. Ramos-Brieva JCA (1986) Validation of the Castillian version of the Hamilton Rating Scale for Depression [in Spanish]. Actas Luso Esp. Neurol Psiquiatr Cienc.Afines 14:324-334. PMID: 3776732
39. Bobes J, García-Portilla MP, Bascarán MT, Sáiz PA, Bousoño M (2002) Banco de instrumentos básicos para la práctica de la psiquiatría clínica. Barcelona: Psiquiatría. PMID: 1948546
40. Endincott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771. PMID: 938196
41. McLellan AT, Kushner H, Metzge D, Peters R, Smith I, Grissom G, et al. (1992) The fifth edition of the addiction severity index. J Subst Abuse Treat 9:199-213. PMID: 1334156
42. National Institute for Health and Clinical Excellence (NICE) (2009) Depression in adults with a chronic physical health problem: treatment and management. London: UK NICE guidance.
43. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013) Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150:384-388. doi: 10.1016/j.jad.2013.04.028 PMID: 23759278
44. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0. http://www.R-project.org. Accessed December 21, 2008.
45. Birchwood M, Iqbal Z, Upthegrove R (2005) Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations. Eur Arch Psychiatry Clin Neurosci 255:202-212. PMID: 15995904
46. Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, Nelson EC, et al. (2004) Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry 61:,1026-1032. PMID: 15466676
47. Arendt M, Rosenberg R, Fjordback L, Brandholdt J, Foldager L, Sher L, et al. (2007) Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. Psychol Med 37: 935-945. PMID: 17202003
48. Degenhardt L, Coffey C, Moran P, Carlin JB., Patton GC (2007) The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. Addiction 102:1076-1084. PMID: 17567396
49. Tomlinson KL, Tate SR, Anderson KG. McCarthy DM Brown SA(2006) An examination of self-medication and rebound effects: psychiatric symptomatology before and after alcohol or drug relapse. Addict Behav 31:461-474. PMID: 15972246
50. Bossong MG, Van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM (2013) The endocannabinoid system and emotional processing: a pharmacological fMRI study with Δ9-tetrahydrocannabinol. Eur Neuropsychopharmacol 23:1687-1697. doi: 10.1016/j.euroneuro.2013.06.009 PMID: 23928295
51. Campos AC, Moreira FA, Gomes FV Del Bel EA, Guimarães FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans R Soc Lond B Biol Sci 367:3364-3378. doi: 10.1098/rstb.2011.0389 PMID: 23108553
52. Secora AM, Eddie D, Wyman BJ, Brooks DJ, Mariani JI, Levin FR (2010) A comparison of psychosocial and cognitive functioning between depressed and non-depressed patients with cannabis dependence. J Addict Dis 29:325-337. doi: 10.1080/10550887.2010.489444 PMID: 20635282